Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Listed
Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,836 across all filing types
Latest filing 2026-04-14 Earnings Release
Country DK Denmark
Listing CO GMAB · 20 venues

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
Earnings Release Classification · 75% confidence The document is a company press release titled “Genmab Announces Net Sales of DARZALEX®…for First Quarter of 2026” that provides key financial highlights (net sales figures) for the quarter. It is not a full interim report but rather an initial announcement of quarterly results. This matches the definition of an Earnings Release (ER). Q1 2026
2026-04-14 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
Earnings Release Classification · 75% confidence The document is a corporate press release announcing first‐quarter net sales figures for DARZALEX®—a high‐level quarterly financial metric—and includes typical earnings-style bullet points and forward‐looking disclaimers. It is not a full interim report (IR), not a management discussion, and not an announcement of a separate report publication. This fits the definition of an Earnings Release (initial announcement of quarterly/periodical financial results with key highlights only). Q1 2026
2026-04-14 English
6-K - GENMAB A/S (0001434265) (Filer)
Director's Dealing Classification · 95% confidence The document is a Form 6-K filed by Genmab A/S, which is a report of a foreign private issuer pursuant to SEC rules. The document includes an exhibit described as a company announcement about transactions with shares and linked securities made by managerial employees and their closely associated persons. The document length is 1715 characters, which is relatively short and primarily serves as a notification of insider transactions rather than a full financial report or earnings release. The key content is about managerial employees' share transactions, which aligns with the definition of Director's Dealing filings. Therefore, the document is best classified as a Director's Dealing report (DIRS).
2026-04-01 English
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Director's Dealing Classification · 95% confidence The document is a company announcement disclosing transactions in shares and linked securities by managerial employees and their closely associated persons, in accordance with Article 19 of the Market Abuse Regulation. It details insider acquisitions due to vesting of restricted stock units by executives. This matches the definition of a Director’s Dealing report (insider transactions by directors/executives).
2026-04-01 English
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Director's Dealing Classification · 95% confidence The document is a company announcement disclosing transactions in shares and linked securities made by managerial employees and their closely associated persons under Article 19 of Regulation 596/2014 on Market Abuse. This corresponds to insider transactions by directors/executives rather than a corporate report or financial release. Therefore, it fits the “Director’s Dealing” category (Code: DIRS).
2026-04-01 English
6-K - GENMAB A/S (0001434265) (Filer)
Major Shareholding Notification Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Genmab A/S, with the SEC. It includes an exhibit index referencing a 'Major Shareholder Announcement' and 'Orbis Shareholder Notification.' The document is short (1649 characters) and primarily serves as a report filing with exhibits related to shareholder notifications. There is no detailed financial data or report content, only references to shareholder notifications. Form 6-K filings often contain various types of announcements, but given the exhibit descriptions and the nature of the content, this filing corresponds to a Major Shareholding Notification.
2026-04-01 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.